09/04/2026
Forbes profiles Rome's Angelini family — a fourth-generation Italian pharma dynasty Forbes puts at about $10 billion — and its push into the United States.
Angelini Pharma closed a $4.1 billion cash deal for Catalyst Pharmaceuticals on July 16, 2026, paying $31.50 a share and delisting the Florida rare-disease biotech from Nasdaq. Italy's CDP Equity put in about €1 billion for a 23.5% stake; Blackstone added about €1 billion in preferred equity.
The family group dates to 1919. Forbes frames the Catalyst buy as the ticket into America's brain-health and rare-disease market — not a cosmetic expansion of an already global name.
More soon on FilingExpress.